Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 4:12:1527271.
doi: 10.3389/fcvm.2025.1527271. eCollection 2025.

Research status of subclinical hypothyroidism promoting the development and progression of cardiovascular diseases

Peijie Wang  1 , Weiming Zhang  1 , Haiyan Liu  1   2
Affiliations
Review

Research status of subclinical hypothyroidism promoting the development and progression of cardiovascular diseases

Peijie Wang et al. Front Cardiovasc Med. .

Abstract

In recent years, the incidence of cardiovascular disease (CVD) has risen steadily, significantly impacting public health. Subclinical hypothyroidism (SCH) remains a controversial risk factor for CVD. This review examines the associations between SCH and dyslipidemia, carotid intima-media thickness (C-IMT), cardiac dysfunction, and cardiovascular event risk. Evidence suggests SCH may exacerbate atherosclerosis and cardiac dysfunction through mechanisms such as increased LDL synthesis, oxidative stress, and impaired vascular endothelial function. However, the causal link between SCH and cardiovascular outcomes remains unclear due to study design heterogeneity and overreliance on TSH levels. Elevated TSH may not solely reflect thyroid dysfunction but could also indicate compensatory responses to inflammation, aging, or stress. Large-scale studies like NHANES and IPD meta-analyses show a strong association between SCH and cardiovascular risk in younger populations, which diminishes in older adults due to physiological TSH increases. The cardiovascular benefits of levothyroxine (L-T4) therapy in SCH patients are limited, especially in older individuals, where a narrow therapeutic window increases side effect risks. Studies relying solely on TSH as a diagnostic and therapeutic target have significant limitations, as TSH cannot distinguish adaptive thyroid adjustments from pathological states and overlooks the role of free thyroid hormones (FT3/FT4). Future research should integrate multi-dimensional markers (such as oxidative stress indicators, vascular elasticity measures, and thyroid antibody status) and adopt longitudinal study designs to more accurately assess the clinical significance of SCH.

Keywords: TSH; atherosclerosis; cardiovascular disease; diastolic heart function; levothyroxine; lipid disorders; subclinical hypothyroidism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Impact of elevated TSH in subclinical hypothyroidism on lipid metabolism and cardiac function.
See this image and copyright information in PMC

References

    1. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. (2014) 24(12):1670–751. 10.1089/thy.2014.0028 - DOI - PMC - PubMed
    1. Sue LY, Leung AM. Levothyroxine for the treatment of subclinical hypothyroidism and cardiovascular disease. Front Endocrinol (Lausanne). (2020) 11:591588. 10.3389/fendo.2020.591588 - DOI - PMC - PubMed
    1. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. (2017) 376(26):2534–44. 10.1056/NEJMoa1603825 - DOI - PubMed
    1. Patrizio A, Ferrari SM, Elia G, Ragusa F, Balestri E, Botrini C, et al. Hypothyroidism and metabolic cardiovascular disease. Front Endocrinol (Lausanne). (2024) 15:1408684. 10.3389/fendo.2024.1408684 - DOI - PMC - PubMed
    1. Brent GA. Mechanisms of thyroid hormone action. J Clin Invest. (2012) 122(9):3035–43. 10.1172/JCI60047 - DOI - PMC - PubMed

LinkOut - more resources